Cited by 261Attention Deficit Hyperactivity DisorderBehavioral and Psychological StudiesChild and Adolescent Psychosocial and Emotional Development

Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review

Chan, Eugenia, Fogler, Jason M., Hammerness, Paul G.·2016·JAMA

Abstract

Importance Although attention-deficit/hyperactivity disorder (ADHD) is highly prevalent in adolescents and often persists into adulthood, most studies about treatment were performed in children. Less is known about ADHD treatment in adolescents. Objective To review the evidence for pharmacological and psychosocial treatment of ADHD in adolescents. Evidence review The databases of CINAHL Plus, MEDLINE, PsycINFO, ERIC, and the Cochrane Database of Systematic Reviews were searched for articles published between January 1, 1999, and January 31, 2016, on ADHD treatment in adolescents. Additional studies were identified by hand-searching reference lists of retrieved articles. Study quality was rated using McMaster University Effective Public Health Practice Project criteria. The evidence level for treatment recommendations was based on Oxford Centre for Evidence-Based Medicine criteria. Findings Sixteen randomized clinical trials and 1 meta-analysis, involving 2668 participants, of pharmacological and psychosocial treatments for ADHD in adolescents aged 12 years to 18 years were included. Evidence of efficacy was stronger for the extended-release methylphenidate and amphetamine class stimulant medications (level 1B based on Oxford Centre for Evidence-Based Medicine criteria) and atomoxetine than for the extended-release α2-adrenergic agonists guanfacine or clonidine (no studies). For the primary efficacy measure of total symptom score on the ADHD Rating Scale (score range, 0 [least…

Integrity signals

Registry

Crossref · 10.1001/jama.2016.5453

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Extended-release stimulant formulations offer sustained symptom control, making them particularly beneficial for school-aged children and adolescents.

    “Extended-release formulations offer sustained symptom control, making them particularly beneficial for school-aged children and adolescents [113].”
  • Many adolescents discontinue ADHD treatment despite ongoing symptoms, which can negatively impact academic and social development.

    “Many adolescents discontinue treatment despite ongoing symptoms, which can negatively impact academic and social development [113].”
  • Behavioral therapy appears to have a greater impact on overall impairment, while medication is more effective in reducing core ADHD symptoms.

    “Behavioral therapy appears to have a greater impact on overall impairment, while medication is more effective in reducing core ADHD symptoms [113].”
  • Research does not indicate a strong link between stimulant medication use and future substance abuse.

    “There continues to be concern about long-term use and the potential for misuse, though research does not indicate a strong link between stimulant medication use and future substance abuse [113].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chan, E., Fogler, J. M., & Hammerness, P. G.
Affiliations
Boston Children's Hospital (US)
Venue
JAMA
Published
2016-05-10
Volume
315
Issue
18
Pages
1997
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2391879726
Cited by
261
References
17
Citations by year
2026: 7 · 2025: 17 · 2024: 17 · 2023: 22 · 2022: 32 · 2021: 22 · 2020: 45 · 2019: 26 · 2018: 31 · 2017: 32 · 2016: 10
FWCI
29.67
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
attention deficit hyperactivity disorder, adolescents, ADHD medication, extended-release methylphenidate, atomoxetine, guanfacine, clonidine, psychosocial interventions, behavioral interventions, cognitive behavioral therapy, skills training, emotional and behavioral problems, interpersonal functioning, motivation enhancement, contingency management
MeSH terms
Atomoxetine Hydrochloride, Adolescent, Amphetamines, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Clonidine, Delayed-Action Preparations, Humans, Methylphenidate, Motivation, Psychotherapy, Randomized Controlled Trials as Topic, Guanfacine, Adrenergic alpha-2 Receptor Agonists, Social Skills

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review